AstraZeneca, the U.K. drugmaker, posted higher second‑quarter revenue, driven by growth in oncology sales, and reaffirmed its 2030 revenue target after a clinical‑trial failure earlier this month.

Total revenue for Q2 reached $15.38 billion, a rise from $14.46 billion a year earlier and a 5% increase when adjusted for currency changes. Analysts had projected $15.42 billion for the period, according to Visible Alpha consensus estimates, indicating the company outperformed expectations.

The firm reported a 15% jump in oncology product revenue at constant currency, effectively counterbalancing declines in its cardiovascular, renal, metabolism, and infectious‑disease sectors. This robust oncology performance underlines the company's strategic focus on life‑saving therapies while maintaining its long‑term revenue outlook.

The results suggest that despite setbacks in other therapeutic areas, AstraZeneca’s oncology pipeline remains a key growth driver. Management continues to emphasize research and development investments, positioning the company to meet its mid‑century financial goals.